DEVELOPMENT AND VALIDATION OF STABILITY INDICATING CHROMATOGRAPHIC METHOD FOR SIMULTANEOUS ESTIMATION OF SACUBITRIL AND VALSARTAN IN PHARMACEUTICAL DOSAGE FORM

SHWETA MISHRA*, C. J. PATEL†, M. M. PATEL‡

*Department of Pharmaceutical Analysis, Gujarat Technological University, Ahmedabad, Gujarat, India, †Department of Pharmaceutical Analysis, Shree Swaminarayan Sanskar Pharmacy College, Gandhinagar, Gujarat, India, ‡Principal, Shree Swaminarayan Sanskar Pharmacy College, Gandhinagar, Gujarat, India
Email: shwetamishra821@yahoo.com

Received: 13 Apr 2017, Revised and Accepted: 22 Aug 2017

ABSTRACT

Objective: This study aims to develop and validate a stability indicating HPLC method for simultaneous estimation of sacubitril and valsartan in pharmaceutical dosage form.

Methods: Sacubitril and valsartan separation were achieved by LC-20 AT C18 (250 mm x 4.6 mm) column and buffer (potassium phosphate, pH 3.0): methanol (50:50) as mobile phase, at a flow rate of 1 ml/min (millilitre per minute). Detection was carried out at 224 nm (nanometer). The different HPLC experimental parameters were optimized and the method was validated according to the standard guideline. Forced degradation experiments were carried out by exposing sacubitril and valsartan standard and sample for thermal, photolytic, oxidative and acid-base hydrolytic stress conditions.

Results: Retention time of sacubitril and valsartan were found to be 4.170 min (minute) and 6.530 min (minute) respectively. The method has been validated for linearity, accuracy, precision, LOD, and LOQ. Linearity observed for sacubitril is 12.25-36.75 μg/ml (microgram per millilitre) and for valsartan is 12.75-38.25 μg/ml (microgram per millilitre). The results showed that sacubitril and valsartan and the other degradation products were fully resolved and thus the proposed method is stability-indicating.

Conclusion: The proposed HPLC method was found to be simple, specific, precise, accurate, rapid and economical for simultaneous estimation of valsartan and sacubitril in bulk and tablet dosage form. Thus the validated economical method was applied for forced degradation study of sacubitril and valsartan tablet.

Keywords: Sacubitril, Valsartan, RP-HPLC, Stability indicating RP-HPLC method, Validation

INTRODUCTION

Sacubitril is chemically 4-[[2S, 4R]-5-ethoxy-4-methyl-5-oxo-1-(4-phenyl-phenyl) pentan-2-yl] amino]-4-oxobutanoic acid [1]. Sacubitril is an antihypertensive drug used in combination with valsartan for the treatment of heart failure. [2-3]. Valsartan is a nonpeptide, orally active and specific angiotensin II receptor blocker acting on the AT1 receptor subtype. Valsartan is chemically N-(1-oxopentyl)-N-[[2- (1Htetrazol-5-yl)]L,1’-biphenyl]-4-yl]methyl]-Lvaline [4-7]. Methods such as HPLC [8-10], LC-MS [11-12], protein precipitation [13] and simultaneous UV-spectrophotometric methods [14-15] are reported for estimation of valsartan alone or in combination with other agents. A literature search reveals that only two analytical methods were reported for simultaneous estimation of sacubitril and valsartan from rat plasma using LC-MS/MS [16] and from a synthetic mixture using HPLC [17]. There is no stability indicating analytical methods were reported for simultaneous estimation of sacubitril and valsartan. Hence a simple, rapid, sensitive and accurate stability indicating HPLC method was developed for the simultaneous estimation of sacubitril and valsartan from API and pharmaceutical dosage form.

MATERIALS AND METHODS [17]

Materials and reagents

Acetonitrile, potassium di-hydrogen phosphate, orthophosphoric acid and methanol of HPLC and AR grade were procured from Merck and Rankem lab ltd. Sacubitril and valsartan standards were received as gift samples from Yash Pharma and RPG Life Science, Ahmedabad, India, respectively.

Equipment

Chromatographic separation was performed on HPLC system consist of model Shimadzu LC-20 AT having a SPD-20AT detector and rheodyne injector with 20μl loop volume. Spinchrom software was applied for data collecting and processing. UV spectrophotometer which consists of model Systronic 119 is also used to measure the wavelength of the solution of Sacubitril and Valsartan.

Fig. 1: Sacubitril structure from pub chem

Fig. 2: Valsartan structure from pub chem

© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
DOI: http://dx.doi.org/10.22159/ijap.2017v9i5.19139
Preparation of standard stock solution
Accurately weighed quantity of 24.5 mg (milligram) sacubitril and 25.5 mg (milligram) valsartan API were transferred into 100 ml (milliliter) volumetric flask and dissolved in HPLC grade methanol using ultra sonication and diluted up to mark to give a stock solution having concentration of 245 μg/ml sacubitril and 255 μg/ml valsartan.

Preparation of working standard solution
From above standard stock solution of sacubitril and valsartan, 1 ml of solution was taken into 10 ml volumetric flask and was made to the mark with the mobile phase to get 24.5 μg/ml of sacubitril and 25.5 μg/ml of valsartan.

Preparation of sample stock solution
The average weight of 10 tablets was determined and was ground in a mortar. Sample stock solution was prepared by dissolving tablet powder equivalent to 24.5 mg of sacubitril or 25.5 mg of valsartan was transferred to 100 ml volumetric flask. Then 60 ml methanol was added and sonicated for 5 min to ensure complete solubilization of drug. After sonication, volume was made up to the mark with methanol. Filter the stock solution with whatman filter paper and the final filtrate is collected as sample stock solution.

Chromatographic conditions
A BDS hypersil C18 (250*4.6 mm, 5 μm) column was used as the stationary phase. A mixture of buffer (pH 3.0) and methanol in the ratio of (50:50 %v/v) was used as a mobile phase and pH 3.0 adjusted with ortho phosphoric acid. It was filtered through 0.45μ (micron) membrane filter and degassed. The mobile phase was pumped at 1.0 ml/min. The eluents were monitored at 224 nm. The injection volumes of sample and standard were 20μl (microliter). Total run time is 10 min.

![Fig. 3: Chromatogram of sacubitril and valsartan](image)

The developed Method was validated for linearity, precision, accuracy, robustness and is applied for forced degradation studies as per the ICH guidelines [18-23]

**RESULTS AND DISCUSSION**

**Method validation**
The described method has been validated which include parameters like system suitability, linearity, accuracy, precision, robustness, LOD (limit of detection) and LOQ (limit of quantification).

**System suitability**
System suitability and chromatographic parameters were validated such as resolution, theoretical plates, and the tailing factor was calculated. The results are given in table 1.

| System suitability parameter | Sacubitril | Valsartan |
|-----------------------------|------------|-----------|
| Retention time (min)        | 4.170      | 6.530     |
| Theoretical plate number (N)| 4915       | 6320      |
| Tailing factor (T)          | 1.313      | 1.523     |
| Resolution(R)              | 8.332      |           |

**Linearity**
The linearity of this method was evaluated by linear regression analysis and calculated by the least square method and studied by preparing standard solutions of sacubitril and valsartan at different concentration levels. The calibration curve showed (Fig. 4 and 5) good linearity in the range of 12.25-36.75 µg/ml for sacubitril with a correlation coefficient (r²) of 0.999 and 12.75-38.25 µg/ml for valsartan with a correlation coefficient (r²) of 0.999. Results are given in table 2.

| Drug      | Conc* (µg/ml) | Area    |
|-----------|---------------|---------|
| Sacubitril| 12.25         | 2240.161|
|           | 18.375        | 3307.088|
|           | 24.5          | 4521.210|
|           | 30.625        | 5566.676|
|           | 36.75         | 6772.742|
| Valsartan | 12.75         | 1878.693|
|           | 19.125        | 2773.397|
|           | 25.5          | 3791.580|
|           | 31.875        | 4668.280|
|           | 38.25         | 5679.762|

Conc*-concentration
Accuracy

Recovery studies were carried out by addition of the standard drug to the sample at 3 different concentration levels (80%, 100% and 120%) taking into consideration percentage purity of added bulk drug samples. At each concentration, the sample was injected thrice to check repeatability and from the % RSD values it was analyzed that the method was accurate as % recovery values found to be in the range of 99.72-100.02% for the Sacubitril and 99.87-100.17% for valsartan at three different concentrations 80%, 100%, 120%.

The results are given in table 3 and 4.

| Conc* (%) | Sample amount (µg/ml) | Amount added (µg/ml) | Amount recovered (µg/ml) | % recovery | % mean recovery±SD* |
|----------|-----------------------|----------------------|--------------------------|------------|---------------------|
| 80%      | 12.25                 | 9.8                  | 9.674                    | 98.71      | 99.61±0.79          |
|          | 12.25                 | 9.8                  | 9.796                    | 99.96      |
|          | 12.25                 | 9.8                  | 9.816                    | 100.16     |
| 100%     | 12.25                 | 12.25                | 12.129                   | 99.01      | 99.57±0.53          |
|          | 12.25                 | 12.25                | 12.259                   | 100.07     |
|          | 12.25                 | 12.25                | 12.203                   | 99.61      |
| 120%     | 12.25                 | 14.7                 | 14.694                   | 99.96      | 99.59±0.41          |
|          | 12.25                 | 14.7                 | 14.574                   | 99.14      |
|          | 12.25                 | 14.7                 | 14.650                   | 99.66      |

SD*—standard deviation, Conc*—concentration, Number of experiments (n)-3

| Conc* (%) | Sample amount (µg/ml) | Amount added (µg/ml) | Amount recovered (µg/ml) | % recovery | % mean recovery±SD* |
|----------|-----------------------|----------------------|--------------------------|------------|---------------------|
| 80%      | 12.75                 | 10.2                 | 10.067                   | 98.70      | 99.92±1.13          |
|          | 12.75                 | 10.2                 | 10.294                   | 100.92     |
|          | 12.75                 | 10.2                 | 10.215                   | 100.15     |
| 100%     | 12.75                 | 12.75                | 12.622                   | 99.00      | 99.63±0.65          |
|          | 12.75                 | 12.75                | 12.88                    | 100.30     |
|          | 12.75                 | 12.75                | 12.699                   | 99.60      |
| 120%     | 12.75                 | 15.3                 | 15.317                   | 100.11     | 99.63±0.49          |
|          | 12.75                 | 15.3                 | 15.168                   | 99.13      |
|          | 12.75                 | 15.3                 | 15.247                   | 99.65      |

SD*—standard deviation, Conc*—concentration, Number of experiments (n)-3

Table 3: Accuracy data for sacubitril

Table 4: Accuracy data for valsartan
Precision

Repeatability
A standard solution containing sacubitril (24.5 µg/ml) and valsartan (25.5 µg/ml) was injected six times and areas of peaks were measured and % RSD was calculated. The results are given in table 5.

Intraday precision
A standard solution containing (12.25, 24.5, 36.75 µg/ml) of sacubitril and (12.75, 25.5, 38.25 µg/ml) of valsartan were analyzed three times on the same day and % RSD was calculated. The results are given in table 6.

Interday precision
A standard solution containing (12.25, 24.5, 36.75 µg/ml) of sacubitril (12.75, 25.5, 38.25 µg/ml) of valsartan were analyzed three times on a different day and % RSD was calculated. The results are given in table 7.

Table 5: Repeatability data for sacubitril and valsartan

| Drug    | Conc* (µg/ml) | Area  | Mean±SD* (n=6) | % RSD* |
|---------|--------------|-------|----------------|--------|
| Sacubitril | 24.5        | 4503.25 | 4506.15±25.56 | 0.57   |
|          | 4457.79     | 4521.20 |                |        |
|          | 4530.26     | 4507.76 |                |        |
|          | 4516.61     |        |                |        |
|          | 3776.45     | 3772.76±32.26 | 0.86   |
|          | 3784.03     | 3782.86 |                |        |
|          | 3799.17     | 3780.24 |                |        |
|          | 3797.81     |        |                |        |

SD* - standard deviation, RSD* - relative standard deviation, Conc* - concentration, Number of experiments (n)-6

Table 6: Intraday data for sacubitril and valsartan

| Drug    | Conc* (µg/ml) | Area mean±SD* (n=3) | % RSD* |
|---------|--------------|---------------------|--------|
| Sacubitril | 12.25       | 2223.62±15.41     | 0.63   |
|          | 24.5        | 4475.65±1.86      | 1.16   |
|          | 36.75       | 6728.43±32.64     | 0.49   |
|          | 12.75       | 1858.60±20.77     | 1.12   |
|          | 25.5        | 3745.33±5.148     | 1.37   |
|          | 38.25       | 5617.50±6.947     | 1.24   |

SD* - standard deviation, RSD* - relative standard deviation, Conc* - concentration, Number of experiments (n)-3

Table 7: Interday data of sacubitril and valsartan

| Drug    | Conc* (µg/ml) | Area mean±SD* (n=3) | % RSD* |
|---------|--------------|---------------------|--------|
| Sacubitril | 12.25       | 2218.93±17.50      | 0.79   |
|          | 24.5        | 4480.94±30.84      | 0.69   |
|          | 36.75       | 6727.83±20.15      | 0.30   |
|          | 12.75       | 1850.82±28.78      | 1.55   |
|          | 25.5        | 3732.18±6.354      | 1.70   |
|          | 38.25       | 5619.57±45.30      | 0.81   |

SD* - standard deviation, RSD* - relative standard deviation, Conc* - concentration, Number of experiments (n)-3

Robustness
Small deliberate changes in chromatographic conditions such as a change in mobile phase ratio (+2 %), change in pH (+2 units) and flow rate (+2 units) were studied to determine the robustness of the developed RP-HPLC method for the analysis of sacubitril and valsartan. The results are given in table 8 and 9.

Table 8: Robustness data for sacubitril

| Drug    | Area at flow rate (+0.2 ml/min) | Area at flow rate (-0.2 ml/min) | Area at pH (+0.2) | Area at pH (-0.2) | Area at mobile phase (+2) | Area at mobile phase (-2) | % RSD* |
|---------|--------------------------------|---------------------------------|-------------------|-------------------|--------------------------|--------------------------|--------|
| Sacubitril | 46.30.12          | 436.685                         | 457.39            | 425.50            | 458.41                   | 4334.83                  | 0.88   |
|          | 468.80            | 441.700                         | 464.53            | 432.41            | 469.58                   | 4498.15                  |        |
|          | 47.06.76          | 443.521                         | 466.51            | 435.43            | 465.683                  | 4439.65                  |        |

RSD* - relative standard deviation, Number of experiments (n)-3
Table 9: Robustness data for valsartan

| Drug   | Area at flow rate (-0.2 ml/min) | Area at flow rate (+0.2 ml/min) | Area at pH (-0.2) | Area at pH (+0.2) | Area at mobile phase (-2) | Area at mobile phase (+2) |
|--------|---------------------------------|---------------------------------|-------------------|------------------|--------------------------|--------------------------|
| Valsartan | 3917.08                         | 3681.51                         | 3879.05           | 3605.61          | 3875.17                  | 3674.13                  |
|        | 3827.40                         | 3601.23                         | 3994.17           | 3526.61          | 3777.54                  | 3696.78                  |
|        | 3947.18                         | 3719.47                         | 3909.24           | 3650.86          | 3909.63                  | 3723.20                  |
| % RSD' | 1.60                            | 1.65                            | 0.39              | 1.75             | 1.78                     | 0.66                     |

RSD': relative standard deviation, Number of experiments (n)=3

Limit of detection (LOD) and limit of quantification (LOQ)

The LOD and LOQ were found to be 0.85µg/ml and 2.580µg/ml for sacubitril and 0.89µg/ml and 2.687µg/ml for valsartan estimated by using the standard formulas. The low values of LOD and LOQ illustrate that the developed method was sensitive, accurate and precise as it can detect and quantify with very low concentration. The result is given in table 10.

Table 10: LOD and LOQ data for sacubitril and valsartan

| Drug | LOD' | LOQ' |
|------|------|------|
| Sacubitril | 0.85(µg/ml) | 2.580(µg/ml) |
| Valsartan  | 0.89(µg/ml) | 2.687(µg/ml) |

LOD': limit of detection, LOQ': limit of quantification

Method development

ICH prescribed stress conditions such as acidic, basic, oxidative, thermal and photolytic stresses were carried out.

Acid degradation

Acid decomposition studies were performed by refluxing 1 ml of sample stock solution was transferred into 10 ml of volumetric flask. 2 ml of 0.1 N HCl solutions were added and mixed well and put for 4 h at 70 °C 250 ml round bottom flask. After a time period, the content was cooled to room temperature. Then the volume was adjusted with diluent to get 24.5μg/ml for sacubitril and 25.5μg/ml for valsartan. After making final solutions, it is injected into HPLC and the peak area and peak shapes were observed. Chromatogram of acid degradation on sample solution is shown below in fig. 6.

Base degradation

Basic decomposition studies were performed by refluxing 1 ml of sample stock solution was transferred into 10 ml of volumetric flask. 2 ml of 0.1 N NaOH solutions were added and mixed well and put for 4 h at 70 °C 250 ml round bottom flask. After a time period, the content was cooled to room temperature. Then the volume was adjusted with diluent to get 24.5μg/ml for sacubitril and 25.5μg/ml for valsartan. After making final solutions, it is injected into HPLC and the peak area and peak shapes were observed. Chromatogram of base degradation on sample solution is shown below in fig. 7.
Oxidative degradation

Oxidative decomposition studies were performed by refluxing 1 ml of sample stock solution was transferred into 10 ml of volumetric flask. 2 ml of 3% H₂O₂ solutions was added and mixed well and put for 4 h at 70 °C. 250 ml round bottom flask. After a time period, the content was cooled to room temperature. Then the volume was adjusted with diluent to get 24.5μg/ml for sacubitril and 25.5μg/ml for valsartan. After making final solutions, it is injected into HPLC and the peak area and peak shapes were observed. Chromatogram of oxidative degradation on sample solution is shown below in fig. 8.

![Fig. 7: Sacubitril and valsartan base degradation sample at 4 h](image)

Thermal degradation

Thermal degradation studies were performed by taking 1 ml of sample stock solution was transferred into 10 ml of volumetric flask. The volumetric flask was stored in an oven at 110 °C for 4 h. Then the volume was adjusted with diluent to get 24.5μg/ml for sacubitril and 25.5μg/ml for valsartan. After making final solutions, it is injected into HPLC and the peak area and peak shapes were observed. Chromatogram of thermal degradation on sample solution is shown below in fig. 9.

![Fig. 8: Sacubitril and valsartan oxidation degradation sample at 4 h](image)

Photolytic degradation

Photo degradation studies were performed by taking 1 ml of sample stock solution was transferred into 10 ml of volumetric flask. The volumetric flask was kept in UV chamber for 72 h. Then the volume was adjusted with diluent to get 24.5 μg/ml for sacubitril and 25.5μg/ml for valsartan. After making final solutions it is injected into HPLC and the peak area and peak shapes were observed. Chromatogram of photo degradation on sample solution is shown below in fig. 10.

![Fig. 9: Sacubitril and valsartan thermal degradation sample at 4 h](image)

![Fig. 10: Sacubitril and valsartan photo degradation sample at 72 h](image)
Sacubitril and valsartan undergoes significant degradation in acid, base, peroxide, thermal and UV. Comparatively, more degradation was found with acid and peroxide for sacubitril and with thermal for valsartan. Hence, a method of the analysis of sacubitril and valsartan in tablet dosage form shows that the degradation product doesn’t interfere with the analytical determination. Hence the proposed analytical method is also useful for the determination of sacubitril and valsartan stability in a sample of the pharmaceutical dosage form.

CONCLUSION

Stability indicating RP-HPLC methods have been developed and validated for the determination of sacubitril and valsartan in tablet dosage form. The methods are found to be specific as there was no interference of any co-eluting impurities after stress degradation study. The degraded products are well resolved, indicating the method can also be useful for determination of degraded products. The proposed method is found to be simple, accurate, precise and robust. Hence, it can be used successfully for the routine analysis of sacubitril and valsartan in pharmaceutical dosage forms and for analysis of stability samples obtained during accelerated stability study.

ACKNOWLEDGEMENT

The authors are thankful to Rivan Pharmaceutical Ltd. for providing all the facilities to complete the research work. Special thanks to Yash Pharma and RPG Life Science, Ahmedabad, India, for providing sacubitril and valsartan standards as gift samples.

CONFLICT OF INTERESTS

Declare none

REFERENCES

1. National Center for Biotechnology Information. PubChem Compound Database; CID=9811834. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/9811834. [Last accessed on 10 Mar 2017].
2. Voors AA, Dorhout B, Van Der Meer P. The potential role of valsartan+A+H377 (LQZ696) in the treatment of heart failure. Expert Opin Invest Drugs 2013;22:1041-7.
3. Novartis AG. Novartis’ new heart failure medicine LQZ696, now called Entresto, approved by FDA to reduce the risk of cardiovascular death and heart failure hospitalisation. Available from: http://www.novartis.com/news/media-releases/Novartis-new-heart-failure-medicine-LQZ696-now-called-entresto-approved-fda. [Last accessed on 10 Mar 2017].
4. Budavari S. The Merck index. 14th ed. Whitehouse Station. NJ Merck and Co. Press; 2006.
5. Neil MJ, Smith A, Heckelman PE, Kinney JF. The Merck Index: An Encyclopedia of Chemicals. Edition. 14. Drugs and Biologicals; 2006. p. 1767.
6. Criscione L, Bradley W, Buhlmayer P, Whitebread S, Glazer R, Lloyd P, et al. Clinical advantage of valsartan. Drug Rev 1995;13:230-50.
7. The United States Pharmacopoeia. 31, National Formulary, 26. Vol. 2. US Pharmacopoeia Convention, INC: Rockville M; 2008. p. 3496-8.
8. Kocyigit Kaymacoglu B, Unsalan S, Rolls S. Determination and validation of ketoprofen, pantoprazole, and valsartan together in human plasma by high-performance liquid chromatography. Pharmacie 2006;61:586-9.
9. Daneshbalad N, Lewanzczuk R, Jamali F. High performance liquid chromatographic analysis of angiotensin-II receptor antagonist valsartan using a liquid extraction method. J Chromatogr B: Anal Technol Biomed Sci 2002;766:345-59.
10. Gonzalez L, Lopez JA, Alonso RM, Jimenez RM. Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr A 2002;949-60.
11. Koseki N, Kawachiita H, Hara H, Nima N, Tanaka K, Kawai R, et al. Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2007;43:1769-74.
12. Li H, Wang Y, Jiang Y, Tang Y, Wang J, Zhao L, et al. A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma. J Chromatogr B: Anal Technol Biomed Life Sci 2007;852:436-42.
13. Macke J, Klama J, Ptacek P. Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography. J Chromatogr B: Anal Technol Biomed Life Sci 2006:832:169-72.
14. Satana E, Altinay S, Goger NG, Ozkan SA, Senturk Z. Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC. J Pharm Biomed Anal 2001;5:1009-13.
15. Tatar S, Saglik S. Comparison of UV-and second-derivative-spectrophotometric and LC methods for the determination of Valsartan in a pharmaceutical formulation. J Pharm Biomed Anal 2002;30:371-5.
16. Chunduri BHR, Dannana GS. Development and validation of a reliable and rapid LC-MS/MS method for simultaneous quantification of sacubitril and valsartan in rat plasma and its application to a pharmacokinetic study. Biomed Chromatogr 2016;30:1467-75.
17. Kena H Patel, Shalesh V, Luhar, Sachin B Narkhede. Simultaneous estimation of sacubitril and valsartan in the synthetic mixture by reliable and rapid LC-MS/MS method for simultaneous quantification of sacubitril and valsartan in rat plasma and its application to a pharmacokinetic study. Biomed Chromatogr 2016;30:1467-75.
18. ICH guidelines for the stability of new drug substances and products. Q1A(R2) JICH, Geneva; 2005. p. 1-14.
19. ICH guidelines for validation of analytical procedures: text and methodology, Q2(R1) JICH, Geneva; 2005.
20. Bhatia MS, Kokil SU. Determination and validation of valsartan and its degradation products by isocratic HPLC. J Chem Met 2009;3:1-12.
21. Parambi DT, Mathew M, Ganesan V. A validated stability indicating HPLC method for the determination of valsartan in tablet dosage forms. J Appl Pharm Sci 2011;1:97-9.

22. Ramachandran S, Mandal BK, Navalgund SG. Stability indicating HPLC method for the simultaneous determination of valsartan and ezetimibe in pharmaceuticals. Top J Pharm Res 2014;13:809-17.

23. Khareef M, Malkieh N, Alhasan AM, Shubitah R, Jaradat N, Zaid AN. Tablet formulation and development of a validated stability indicating HPLC method for quantification of valsartan and hydrochlorothiazide combination. Int J Pharm Pharm Sci 2012;4:683-7.

How to cite this article
- Shweta Mishra, CJ Patel, MM Patel. Development and validation of stability indicating a chromatographic method for simultaneous estimation of sacubitril and valsartan in pharmaceutical dosage form. Int J Appl Pharm 2017;9(5):1-8.